Clinical Trials
Health Canada approves Uplizna for rare form of neuromyelitis optica spectrum disorder
Health Canada has approved Uplizna as a monotherapy for adults with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 immunoglobulin G seropositive.
Bridging the ‘vast divide’: Mistrust, bias fuel racial disparities in lupus research
The body of data demonstrating that lupus significantly and disproportionately impacts Black, Hispanic and Asian patients is robust. It should therefore follow that these populations are appropriately represented in clinical trials for the disease.
First patient dosed in phase 2b trial of treatment for agitation in Alzheimer’s disease
IGC Pharma has announced that dosing has commenced at one of its sites participating in a phase 2b clinical trial of a combination therapy for agitation in dementia related to Alzheimer’s disease.
Research collaboration aims to expand recruitment, improve access to clinical trials
K2 Medical Research has partnered with Magruder Eye Institute and RetiSpec in a research pilot to improve access to clinical trials, using AI-driven technology to prescreen eligible candidates in an eye care setting.
Positive data reported from phase 1b/2a study of oral superagonist for epileptic seizures
A clinical-stage biopharmaceutical company has announced positive topline data from a study evaluating a novel, oral 5-HT2C receptor superagonist for seizures associated with developmental and epileptic encephalopathies.
Stuart Therapeutics announces first patient visit in ST-100 trial for dry eye
Stuart Therapeutics has announced the first patient first visit for its phase 3 clinical trial of ST-100 ophthalmic solution for patients with dry eye disease.
VIDEO: Ubrogepant prevents headache when administered in prodromal phase
Treatment with 100 mg of ubrogepant in the prodromal phase prevented development of headaches as soon as 24 hours post-dose compared with placebo, according to study co-author Peter J. Goadsby, MD, PhD, FRS.
First patient dosed in phase 2a study of intranasal MS treatment
A biotechnology company announced the first patient was dosed in its phase 2a clinical trial of intranasal foralumab, a monoclonal antibody treatment for those with non-active secondary-progressive multiple sclerosis.
Partnership to advance novel ALS combination therapy
A pharmaceutical company and a biotechnology firm have announced a development and license agreement for an investigational proprietary biologic combination therapy to treat amyotrophic lateral sclerosis.
Positive interim data shown in phase 1/2 trials of Huntington’s disease therapy
A gene therapy company has announced updated interim data from ongoing United States and European phase 1/2 clinical trials of AMT-130 to treat Huntington’s disease.